This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Central Drugs Laboratories find 46 drug samples not of standard quality for May

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F2gpiGV
via IFTTT

Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qi42rVf
via IFTTT

Jyothy Labs to expand Exo into broader dishwash franchise after Henkel brands exit portfolio

Jyothy Labs is strategically expanding its Exo dishwash brand into a comprehensive franchise following Henkel's exit from Pril and Fa licensing in India. The company remains cautiously optimistic about FY27 growth, focusing on premium products, innovation, and wider distribution despite inflationary pressures. New Exo variants are showing promising consumer response, aiming to boost sales and market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NH5MPcp
via IFTTT

Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tjgNuyO
via IFTTT

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to conclude by July 2026, is a significant step for Sun Pharma's expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x6BPKQN
via IFTTT

Yoga may boost cognition, reduce depression, aid gut health in early Alzheimer's: AIIMS study

A 12-week yoga program has shown promising results for individuals with mild Alzheimer's disease. Researchers at AIIMS, Delhi, observed significant improvements in cognitive function and mood, alongside a healthier gut microbiome. The study suggests yoga may help restore beneficial gut bacteria, potentially influencing the gut-brain axis and offering a valuable complementary therapy for early-stage Alzheimer's and mild cognitive impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xbKZrwE
via IFTTT

Plan in the works to let hospitals import med equipment directly

India's drug regulator is proposing to allow hospitals to directly import advanced medical equipment like MRI and CT scanners, bypassing current import licenses. This move aims to speed up access to cutting-edge technology. However, the domestic medical device industry expresses concern, citing safety risks and the specialized expertise of licensed importers in handling high-risk equipment and ensuring quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iPEWgbe
via IFTTT